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Abstract
Background: Deaths due to vaccine preventable diseases cause a notable proportion of mortality worldwide. To
quantify the importance of vaccination, it is necessary to estimate the burden averted through vaccination. The
Vaccine Impact Modelling Consortium (VIMC) was established to estimate the health impact of vaccination.
Methods: We describe the methods implemented by the VIMC to estimate impact by calendar year, birth year and
year of vaccination (YoV). The calendar and birth year methods estimate impact in a particular year and over the
lifetime of a particular birth cohort, respectively. The YoV method estimates the impact of a particular year’s
vaccination activities through the use of impact ratios which have no stratification and stratification by activity type
and/or birth cohort. Furthermore, we detail an impact extrapolation (IE) method for use between coverage scenarios.
We compare the methods, focusing on YoV for hepatitis B, measles and yellow fever.
Results: We find that the YoV methods estimate similar impact with routine vaccinations but have greater yearly
variation when campaigns occur with the birth cohort stratification. The IE performs well for the YoV methods,
providing a time-efficient mechanism for updates to impact estimates.
Conclusions: These methods provide a robust set of approaches to quantify vaccination impact; however it is vital
that the area of impact estimation continues to develop in order to capture the full effect of immunisation.
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Background
Vaccination is one of the most effective interventions
against infectious diseases and is estimated to prevent
2-3 million deaths annually, with an additional 1.5 mil-
lion deaths that could be averted with improvements in
global vaccination coverage [1]. Vaccines can provide
cost-effective, long-term protection and have resulted in
the eradication of two major pathogens, rinderpest and
smallpox, as well as the local elimination of others, such
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as measles [2, 3]. Most vaccines have been shown to be
safer than therapeutic medicines and are deemed second
only to safe drinking water in terms of public health
benefit [4–6].
Of the burden that does occur due to vaccine pre-
ventable diseases, the majority is in low- and middle-
income countries (LMICs) [7]. In many countries, the lack
of reliable surveillance data and the inability to observe
the burden that would have occurred without vaccina-
tion makes it difficult to directly calculate the mortality
and morbidity prevented by vaccination. Hence, mathe-
matical models are crucial for providing estimates of the
burden averted by immunisation as they can project a no-
vaccination (counterfactual) scenario and scenarios with
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vaccination [8]. The Vaccine Impact Modelling Consor-
tium (VIMC) [9] was established in 2016, formally bring-
ing together several modelling groups and a secretariat
with a history of working together to estimate the impact
of vaccines against ten pathogens, namely, Haemophilus
influenzae type b (Hib), hepatitis B (HepB), human papil-
lomavirus (HPV), Japanese encephalitis, measles, Neisse-
ria meningitidis serogroup A (Meningitis A), rotavirus,
rubella, Streptococcus pneumoniae and yellow fever (YF).
Estimating the impact of vaccination is important as this
reveals the effectiveness of current global vaccination
strategies and whether any changes are needed.
Calculating vaccine impact is complex as for some
pathogens, such as HepB and HPV, the consequences due
to disease are not seen until long after infection. Thus,
any vaccine impact is not immediately evident, but is still
substantial leading to questions around how to appro-
priately attribute the impact of vaccination activities in
order to inform the public and policy makers of their
value. Vaccination activities also face a paradox as “vac-
cines are victims of their own success” [10]. For example,
when the transmission of a fatal disease from an outbreak
is prevented by vaccination, political and public support
is assured. However, when vaccination is successful and
the formerly-feared disease starts disappearing, the ben-
efits of vaccination become less clear whilst the costs
remain visible. As a consequence, public and political sup-
port may begin to decline. The benefits of the success of
vaccination and control of diseases become less obvious
with time, no longer being viewed with the same sense of
urgency.
Throughmathematical modelling of vaccination scenar-
ios, we can explore the impact of vaccination activities
stratified by characteristics such as birth cohort. Mathe-
matical modelling, such as that carried out by the VIMC,
is able to provide estimates of disease burden in terms
of the number of cases, deaths and/or disability adjusted
life years (DALYs). DALYs measure the years of healthy
life lost due to disability from the disease and premature
death. Comparing burden estimates in scenarios with and
without vaccination can then quantify the burden averted
by vaccination. However, impact may be attributed in dif-
ferent ways, some of which may be more appropriate in
some settings than others. For example, one may be inter-
ested in the effect of vaccination on a particular birth
cohort, so the impact of vaccination activities over the
lifespan of that cohort needs to be aggregated. In con-
trast, for advocacy, planning and financing, it is valuable
to ascertain the impact attributable to a particular year’s
vaccination activities.
As the burden in each vaccination scenario is calcu-
lated using mathematical models of pathogen transmis-
sion dynamics and implementation of vaccination activ-
ities, the impact of vaccination will vary depending on
the underlying model being used. The models within
the VIMC vary from being static, whereby the direct
effects of vaccination on FVPs are modelled assuming that
pathogen transmission intensity is not modified by vacci-
nation coverage, to dynamic, whereby infectious disease
transmission dynamics, direct effects of vaccination on
FVPs and herd effects are modelled. Herd effects account
for any indirect effects of immunity (both natural and/or
from vaccination activities) due to a reduction in trans-
mission. For example, an increase in FVPs offers indirect
protection as it reduces the risk of a non-vaccinated indi-
vidual coming into contact with the disease. Herd effects
will not arise for all vaccine preventable diseases, for
example, Japanese encephalitis is vector-borne (i.e. not
transmitted person-to-person) and the majority of cases
are due to spillover events [11]. Hence in this case, FVPs
will not provide protection to others.
The VIMC uses vaccine coverage estimates from the
World Health Organization (WHO), United Nations Chil-
dren’s Fund (UNICEF) and Gavi, the Vaccine Alliance
[12–14]. Due to changes and uncertainties in data on vac-
cination coverage, estimates of coverage are constantly
refined and updated [13], requiring estimates of vaccine
impact to be recalculated accordingly. Whilst mathemat-
ical modelling of vaccine impact is vital to the process
of the VIMC and ascertaining the effect of vaccination,
it can be incredibly computationally expensive and time-
consuming. This limitation sometimes precludes it from
being used for quick updates as new coverage becomes
available; an event which can happen multiple times a
year. As such, the VIMC secretariat has developed an
impact extrapolation (IE) method whereby the impact
ratio (impact per fully vaccinated person) from one mod-
elling exercise can be applied to a new coverage scenario
in order to extrapolate the impact calculation to the latest
coverage estimates.
In this paper, we describe the methods that have been
implemented by the VIMC to calculate the vaccination
impact by calendar year, birth year and year of vaccination
(YoV). To show how thesemethods perform, we use exam-
ples from HepB, measles and YF. Further, we describe an
IE method which facilitates the estimation of impact from
new vaccination coverage scenarios without full model
runs. This is an approximation of the model projections
which, whilst informative, is not a replacement for full
model estimation. The IE does, however, allow for new
approximate estimates to be produced very quickly andwe
detail a number of approaches each with their strengths
and weaknesses.
Methods
We detail a range of methods for calculating the impact of
vaccination (D) defined as the burden averted for a given
disease, country, year and, in some cases, birth cohort.
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Each method is used to address a specific point of inter-
est, such as the number of lives saved by vaccination in
a particular year (calendar year method), the number of
individuals born in a particular year that will be saved due
to vaccination (birth year method), and the number of
individuals that will be saved due to a particular year’s vac-
cination activities (YoV methods). These usually involve
the comparison of a focal scenario, the vaccination sce-
nario we wish to assess, to a counterfactual or baseline
scenario, which is the vaccination scenario we wish to
compare against. We also detail the IE process and the
scenarios carried out. All parameters and variables are
defined in Table 1. Impact ratios are shown in Table 2 and
a summary of the impact methods is shown in Table 3.
Impact by calendar year (cross-sectional impact)
The calendar year method calculates the impact accrued
over all ages for a specific year. It is generally the most
intuitive and frequently used method to calculate the
impact of vaccination. In this case, the vaccine impact,
Db−f (a, c, y), for age a, country c in year y is defined as the
difference in disease burden between baseline and focal
scenarios for a given year, Db−f (a, c, y) = Bb(a, c, y) −
Bf (a, c, y). Here, the baseline scenario can have no vacci-
nation or different coverage to the focal scenario. Aggre-
gating the impact over all ages modelled (Am) means the
impact for a country c in year y is given by D(c, y) =∑
a∈Am Db−f (a, c, y). This does not account for the future
disease burden averted through current vaccine activities.
Impact by birth year (lifetime impact)
The birth year method accounts for the long-term impact
accrued over the lifetime of a particular birth cohort k. For
Table 1 Parameter and variable definitions
Parameter Definition Variable Definition





Bf Burden in focal
scenario
Ym Years evaluated Db−f Difference or impact
between baseline and
focal burden
a Age baseline and focal
scenarios (Bb − Bf )
Av Age at routine
vaccination
ρ Impact ratio (impact
per FVP)
Am Ages modelled D Vaccine impact




Table 2 Stratifications of the impact ratios (ρ)
No stratification: Vaccine
impact does not vary between
vaccination activities or birth
cohorts in a population.
Stratification by activity
type: Vaccine impact varies
between RV and CV but does
not vary across birth cohorts.






cohort: Vaccine impact varies
across birth cohorts in a
population but does not vary
between vaccination activities.
Stratification by activity
type and birth cohort:
Vaccine impact varies between
vaccination activities and birth
cohorts.
ρ(k) = D(k)FVP(k) RV: ρR(k) = DR(k)FVPR(k) and CV:
ρC(k) = DC (k)FVPC (k)
Here, FVPR and FVPC denote fully vaccinated persons (FVPs) due to routine (RV) or
campaign vaccination activities (CV) only; DR and DC denote impact due to RV or CV
only, D denotes impact from both routine and campaign vaccinations, and k
denotes a particular birth cohort
country c, this is given by D(c, k) = ∑y−a=k Db−f (a, c, y),
where y ∈ Ym and a ∈ Am. The duration of modelling
needs to be appropriate to the pathogen of interest as in
some cases, such as HepB, disease occurs later in life. For
example, if we model vaccination for birth cohorts born
from 2000 to 2030 and model disease burden until 2100,
we do not account for the vaccine impact for those born
in 2030 once they are over 70 years old. The method also
does not specifically account for the impact of vaccinat-
ing a cohort outside the cohort vaccinated (e.g. because of
herd protection).
Impact by year of vaccination
The YoV methods are vital for determining the long-term
impact of vaccination due to activities carried out in a par-
ticular year. We obtain the impact ratio, ρ, as the impact
attributable per fully vaccinated person (FVP) calculated
as the coverage × cohort size. This ratio can be stratified
by different characteristics, such as birth cohort in order
to catch temporal changes in transmission or healthcare
or by activity type to capture the differing effects of rou-
tine and campaign vaccination (RV and CV, respectively);
see Table 2 for details. The impact ratio allows effects due
to a particular year’s worth of vaccination to be attributed
to that year. Additionally, the impact ratio can then be pro-
jected with the IE method by updating the impact with
a new estimate of FVPs; see impact extrapolation section
for further details.
Impact by year of vaccination: unstratified impact ratio
The simplest approach to calculate the impact by YoV
is with an unstratified impact ratio which assumes that
the effect of a vaccine is invariant over time and activ-
ity type. As such, the impact ratio, ρ, for a country, c, is
the attributable vaccine impact divided by the number of
FVPs:
Echeverria-Londono et al. BMC Public Health         (2021) 21:2049 Page 4 of 12
Table 3 Summary of methods used by the VIMC for calculating the impact of vaccination (refer to Tables 1–2 for parameter values and
for stratifications of the year of vaccination method, respectively)
Method Definition Advantages Limitations
Calendar year Impact for a particular year Intuitive. Does not account for the long-term
impact of vaccination on individual
disease risk and cannot be linked to
specific vaccination activities.
Birth year Impact for a particular birth cohort Captures the long-term effects of
vaccination in protecting those
vaccinated.
Duration of modelling needs to be
pathogen-appropriate, e.g. the
effects of HepB require a longer
modelling time frame. Does not
account for inter-cohort effects
(e.g. herd protection).
Year of vaccination (YoV) Impact attributed to year in which
vaccination occurred
Possible to assess the effects of a
specific year’s activities and thus
provide a direct comparison of the
number of doses provided and
their effect. This is useful for
planning and economic purposes.
An impact ratio is required which
can be affected by the
years/activities or birth cohorts
included, see Table 2 for details.
Does not account for inter-cohort
effects (e.g. herd protection).
ρ(c) =
∑




a∈Am DS(a, c, y)∑





where Yv − Av refers to cohorts vaccinated in Yv through
RV. Thus, the impact attributed to a year of vaccination is
given by:
D(c, y) = ρ(c) × FVP(c, y), (2)
where FVP(c, y) = FVPR(c, y)+FVPS(c, y) and the impact
ratio is the same across age groups. This method does
not take into account any changes in treatment or trans-
mission over time, nor the differing effects of vaccination
through RV or CV. However, it is less complex to calcu-
late and could be considered a weighted average of impact
ratios for each vaccination activity.
Impact by year of vaccination: impact ratio stratified by
activity type
To calculate the impact by YoV using impact ratios strat-
ified by activity type, we assume that RV and CV, which
target multiple age groups, have different effects; for
example due to dosage clustering. Hence, this method
produces multiple activity-specific impact ratios which
can then be multiplied by the number of FVPs to calculate
impact.
For RV, the impact ratio is defined as the impact for all
cohorts who are vaccinated over time period Yv per the
additional FVPs between the baseline and focal scenarios.
The impact for RV,DR, is given byDbR−fR , where bR and fR
are the baseline and focal RI scenarios, respectively. Here,
the impact ratio for RV is:
ρR(c) =
∑
y−a∈Yv−Av DR(a, c, y)∑
y∈Yv FVPR(c, y)
, (3)
where Yv − Av are cohorts receiving vaccinations in years
Yv. The impact by year of vaccination is then:
DR(c, y) = ρR(c) × FVPR(c, y), (4)
where FVPR are FVPs vaccinated through RV and the
impact ratio is the same across age groups. This does not
account for the impact generated by indirect effects from
and to cohorts not eligible for routine vaccination in Yv,
nor does it account for interactions between RV and CV
that may occur during or before years Y − v.
For CV, the impact ratio is averaged evenly over all ages
across the entire time period (Ym). This is because we do
not attempt to predict future CV coverage after the final
year of credible campaign schedules. Therefore, the only
impact due to CV comes from CV years Yv and all cam-
paign impact for birth cohorts born after this period can
be attributed back to these vaccination years. The impact
of CV, DC , is given by DbC−fC , where bC and fC are the
baseline and focal CV scenarios, respectively. The impact





a∈Am DC(a, c, y)∑
y∈Yv FVPC(c, y)
. (5)
The impact by year of vaccination is then given by the
following:
DC(c, y) = ρC(c) × FVPC(c, y), (6)
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where FVPC are FVPs vaccinated through CV. Again, this
does not account for interactions with the level of routine
coverage across or before the same years.
The aggregated impact by YoV for both activities is the
sum of the impact from RV and CV, i.e. sum of Eqs. 4
and 6.
Impact by year of vaccination: impact ratio stratified by birth
cohort
In this method the impact ratio is invariant to vaccina-
tion activity type. However, vaccine effect is assumed to
vary over time through birth cohorts. This means that
rather than averaging the effect of vaccination over time,
we account for the variation in transmission and health
of the population. This influences how one year’s vacci-
nation may work compared to another. For example, if
therapeutic treatments for a disease improve over time,
we may expect the impact of vaccination in 2050 to be less
than that now as the population is generally healthier. In
this case, the impact ratio is cohort specific, given by the
following equations:
ρ(c, k) = Db−f (c, k)
FVP(c, k)
, (7)
where k is the cohort defined by k = y − a and a ∈
Am. In order to find the impact attributed to one year of
vaccination, all cohort-specific impacts for those cohorts
vaccinated in the year of interest must be aggregated. The




ρ(c, k) × FVP(c, k, y), (8)
Impact by year of vaccination: impact ratio stratified by both
activity type and birth cohort
In the above methods, we illustrate the potential ways the
impact ratio could change between birth cohorts or by
vaccination activity. However, it is likely that in reality the
impact varies with respect to both of these aspects. In
the following method, we use the approach of the activity
stratification over birth cohort to arrive at an impact ratio
per birth cohort and activity. The impact ratios by activity
(R for RV; C for CV) are thus the following:
ρR(c, k) = DR(c, k)FVPR(c, k) , (9)
ρC(c, k) = DC(c, k)FVPC(c, k) . (10)
Therefore the impact by YoV is provided by the sum of
the activity and cohort-specific components:




ρR(c, k) × FVPR(c, k, y) +
∑
k
ρC(c, k) × FVPC(c, k, y).
(11)
Note that in the above method the numerator may
also be affected by vaccination activities experienced by
cohorts around them, so not captured in the denominator.
Hence the impact ratio could potentially be infinite.
Summary of impact methods
We summarise the key features of each vaccine impact
method in Table 3.
Impact extrapolation
As coverage estimates are frequently updated within
the WHO/UNICEF Estimates of National Immunization
Coverage (WUENIC) and Gavi’s Operational Forecast
(OP) [12–14], one of the vital tasks of the VIMC is to
provide updated impact estimates to inform future RV
and CV. Translating these coverage estimates into tangi-
ble estimates of vaccine impact in terms of mortality and
morbidity averted is crucial. However, given the regular
updates of vaccination coverage and the effort and time
required for full model updates across the VIMC, a sim-
plified process, the IE, has been developed to update past
rounds of impact estimates with new coverage data.
The IE is primarily a linear interpolation of current
vaccine impact estimates with new coverage estimates
assuming constant country- and delivery strategy-specific
rates of mortality and morbidity averted per dose of vac-
cine. It can be applied to the YoVmethods as these provide
us with an impact ratio (ρ in Table 2). Hence, when cov-
erage is updated, the updated number of FVPs can be
calculated bymultiplying the new coverage with the target
population. The updated FVPs (FVP∗) are then multiplied
by the previously calculated ρ to calculate the updated
impact (D∗):
D∗(c) = ρ(c) × FVP∗(c). (12)
Models and vaccination scenarios
In this analysis, we focus on calculating impact estimates
for HepB (dynamic model with long-term outcomes and
herd effects), measles (dynamic model with short-term
outcomes and herd effects) and YF (static model with-
out herd effects) [15–18]. Model details are provided in
the supplementary material. We use anonymised coun-
tries for each of the pathogens, denoted by Country A for
HepB, Country B for measles and Country C for YF, with a
focus on the years 2000–2017. The countries were chosen
as they included examples of relevant vaccination activi-
ties over the time period. Standardised demographic data
(live births per year, death rates) are based on the 2017
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United Nations World Population Prospects (UNWPP)
[19]. Immunisation coverage from 1980 to 2016 cor-
responds to the WHO/UNICEF Estimates of National
Immunization Coverage (WUENIC) as published in July
2017 [13], and 2017–2030 coverage corresponds to Gavi’s
October 2017 Operational Forecast (OP) [14, 15]. Using
each of the vaccine impact methods, we calculate the
number of deaths averted due to vaccination over the
years 2000–2017. Though we only show this for 2000–
2017, we are taking into account the impact of vaccination
activities from 2000 to 2030 as we follow individuals
through their lives to capture later deaths averted.
We also investigate the performance of the IE under the
YoVmethods with no stratification, stratification by activ-
ity and cohort separately and in combination by applying
it to HepB, measles and YF in Countries A, B and C
with updated coverage data. More specifically, for each
of these pathogens, we update RI coverage from 1980 to
2017 based on WUENIC published in July 2018 [13], and
2018–2030 routine and campaign coverage is updated to
Gavi’s October 2018 OP [14]. Changing coverage of activ-
ities alters the number of FVPs (population demography
and models remain the same). We then re-run the models
with this updated coverage scenario and compare to the IE
projections in order to determine the reliability of the IE.
All of the analyses were carried out in R and the impact
methods are available through the R package vimpact on
GitHub (https://github.com/vimc/vimpact) [20].
Results
Estimates of the impact of vaccination
From 2000 to 2017, HepB, measles and YF have different
vaccination activities in each of the countries. We anal-
yse the impact calculation methods for RV alone and in
combination with CV.
Only RV exists for HepB; this is given as a birth
dose (soon after birth) and as infant doses (<1 year old)
(Fig. 1A). As HepB-attributable mortality primarily affects
Fig. 1 Fully vaccinated persons (FVPs) and mean estimates of deaths averted for hepatitis B (HepB) in Country A, measles in Country B and yellow
fever (YF) in Country C from 2000 to 2017. (A) FVPs for HepB birth dose (BD routine) and infant dose (routine) routine vaccination activities. FVPs for
first routine dose of a measles containing vaccine and measles campaign activities. FVPs for YF routine and campaign activities. (B) Impact by
calendar and birth year methods. (C) Impact by year of vaccination (YoV) with impact ratio stratified by activity type and birth cohort
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those over 40 years of age, we find that the birth year
method captures a greater impact as it accrues the long-
term benefits of vaccination over the lifetime of birth
cohorts. With the calendar year method accruing the
impact for all ages over a particular year, this long-term
impact is not captured (Fig. 1B). Prior to 2013, YF has rou-
tine infant dose vaccinations (<1 year old) only, with the
calendar year method capturing slightly more impact (rel-
ative to HepB) as yellow fever largely affects those under
30 due to natural immunity acquired with age in older
adults (Fig. 1A–B).
For measles from 2000–2017 in Country B, CV occur
alongside RV. RV provides the first dose of a measles
vaccine to those aged 1 or under (Fig. 1A). As FVPs accu-
mulate, the birth year and calendar year methods show
an increasing number of deaths averted over time. In
comparison to HepB where it is vital that the long-term
benefits are captured, the calendar year method shows a
high impact as measles-related mortality is focused in the
under-5s (Fig. 1B).
The impact of vaccination estimated by the YoV meth-
ods varies over time with the activity stratification show-
ing an averaged impact and the birth cohort stratification
capturing gradual improvements in population health,
particularly when herd effects are modelled. Hence, the
activity stratification initially shows a higher number
of deaths averted than the birth cohort stratification.
Accordingly with RV only for HepB and prior to 2013
for YF, we see that the impact calculated by the activity
stratification is greater as it is averaging the impact over
all FVPs. The impact for the birth cohort stratification
does not surpass the activity stratification within the time
frame of this analysis for these two pathogens (Fig. 1C).
Notably for HepB, with RV occurring in the first year of
life, the impact by year of vaccination and impact by birth
year methods show a similar impact.
For YF, there is one campaign in 2013 which results
in a peak in the deaths averted with the largest impact
seen with the activity stratification. The birth cohort strat-
ification shows a lower impact as this is the first cam-
paign (Fig. 1C). For measles, we see the same pattern
for the first campaign but for subsequent campaigns we
see a higher impact with the birth cohort stratification
because it is capturing the overall improvement in popu-
lation health. Furthermore, herd effects are modelled for
measles which contribute to the birth cohort stratifica-
tion impact increasing as herd effects build up, reducing
transmission in the population (Fig. 1C).
Performance of the impact extrapolation method with
updated coverage compared to model estimates
We explore the IE under the YoV methods with impact
ratios stratified as per Table 2 for scenarios where vacci-
nation coverage is updated from 2017 estimates to those
published in 2018 (as described in Methods; change in
FVPs shown in Figs. 2A and 3A). The accuracy of the
IE projections is determined by comparing to model esti-
mates given the same updated coverage. Vaccine impact,
i.e. deaths averted, by year of vaccination and by year
of birth are visualised in Figs. 2 and 3, respectively, for
Countries A, B and C over the years 2000–2017. The
total relative difference in deaths averted over 2000–2017
between the IE and model estimates are shown in Table 4.
We find that the accuracy of the IE varies depending on
the impact ratio stratification method, underlying model
dynamics and pathogen characteristics.
Using impact ratios without stratification, the IE per-
forms relatively well for HepB in comparison to measles
and YF (Table 4). As HepB only has RV, the activity type
does not need to be taken into account. Furthermore, as
this is given as a birth or infant dose, unstratified impact
ratios would not capture variation in effect but this change
would likely occur subtly over long time periods. Both
RV and CV occur for measles and YF for which the IE
with unstratified impact ratios underestimates the deaths
averted due to the drop in coverage/FVPs in the 2018
coverage scenario prior to 2020 (Figs. 2A,B and 3A,B).
The IE with impact ratios stratified by activity does not
perform well for HepB relative to measles and YF as it
overestimates the impact associated with a change in cov-
erage (Table 4; Figs. 2C and 3C). In the updated coverage
scenario, HepB coverage improves over the years 2017–
2022 creating more FVPs. With the activity stratification,
this coverage improvement is being averaged over the
whole time period. As such, the impact of earlier RV is
artificially inflated. Additionally, as HepB-attributed dis-
ease occurs later in life, vaccinating more people born in
later years will produce herd protection for those born
over 2000–2017.
For measles, the activity stratification viewed by year of
vaccination performs well (Table 4; Figs. 2C and 3C). Sim-
ilar to HepB, measles coverage for RV improves greatly
post-2020 with the 2018 coverage scenario. However, the
IE does not overestimate the impact of this in the same
way as it did for HepB because measles is focused in the
under-5s so creating more FVPs later on does not produce
herd effects for the 2000–2017 birth cohorts.
Using the activity stratification for YF, with changes to
coverage, the IE works well with only a small underesti-
mation of deaths averted (0.84%) by year of vaccination
over 2000–2017 compared to model estimates (Fig. 2C)
as it is a static model with no herd protection. However,
there is larger underestimation of deaths averted (7.41%)
by year of birth (Fig. 3C) as the FVPs vaccinated in the
2000–2017 birth cohorts is lower in the 2018 coverage sce-
nario (Fig. 3A). Furthermore, compared to the unstratified
impact ratio, the impact ratio for CV specifically is smaller
and more sensitive to a reduction in FVPs. In contrast, the
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Fig. 2Model estimates and impact extrapolation showing deaths averted by year of vaccination per year for hepatitis B (HepB) in Country A,
measles in Country B and yellow fever (YF) in Country C from 2000 to 2017 using 2017 coverage (2017 model), 2018 coverage with corresponding
model estimates (2018 model), and 2018 coverage with the impact extrapolation (2017–2018 IE). (A) Fully vaccinated persons (FVPs) in 2017 and
2018. (B) Impact by year of vaccination with unstratified impact ratio. (C) Impact by year of vaccination with impact ratio stratified by activity type.
(D) Impact by year of vaccination with impact ratio stratified by birth cohort. (E) Impact by year of vaccination with impact ratio stratified by activity
type and birth cohort
impact ratio for RV is larger than the unstratified impact
ratio which accounts for the fact that RV will almost
always be given to unvaccinated infants, as opposed to CV
which, as dose distribution is assumed to be random, may
revaccinate individuals who are already immune.
Using the birth cohort stratification, the IE performs
well for HepB but underestimates the number of deaths
averted by year of vaccination and birth year under the
updated coverage scenarios for measles and YF (Table 4;
Figs. 2D and 3D). Although the 2018 coverage scenarios
generally have higher coverage post-2020, the coverage
drops prior to 2020 for measles and YF but for HepB it
improves slightly (Figs. 2A and 3A). As the birth cohort
stratification captures greater yearly variation, it does well
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Fig. 3Model estimates and impact extrapolation showing deaths averted by year of vaccination per birth year for hepatitis B (HepB) in Country A,
measles in Country B and yellow fever (YF) in Country C from 2000 to 2017 using 2017 coverage (2017 model), 2018 coverage with corresponding
model estimates (2018 model), and 2018 coverage with the impact extrapolation (2017–2018 IE). (A) Fully vaccinated persons (FVPs) in 2017 and
2018. (B) Impact by year of birth with unstratified impact ratio. (C) Impact by year of birth with impact ratio stratified by activity type. (D) Impact by
year of birth with impact ratio stratified by birth cohort. (E) Impact by year of birth with impact ratio stratified by activity type and birth cohort
for the smaller change in HepB coverage and shows a cor-
responding decline in impact for measles and YF as it
is more sensitive to changes in coverage than the activ-
ity stratification. This captures a limitation of the birth
cohort stratification as it assumes the impact from RV
and CV will be similar when they could be distinctively
affected by dose wastage i.e. a RV will almost always be
given to a susceptible child whereas campaigns may vac-
cinate individuals who have already been vaccinated, thus
non-intuitively having a smaller impact.
Implementing the IE when stratifying by both activity
and birth cohort results in the IE being sensitive to a com-
bination of factors that affect the activity and birth cohort
stratifications, such as the type of activities occurring,
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Table 4 Relative total difference of impact extrapolation (IE) to model estimates for deaths averted over 2000–2017 (%) by year of
vaccination (YoV) and year of birth (YoB) due to vaccination activities for hepatitis B (HepB) in Country A, measles in Country B and
yellow fever (YF) in Country C
Disease and deaths
averted by YoV/YoB




Activity type and birth
cohort stratification
HepB- YoV -0.86 7.24 0.40 0.30
HepB- YoB -4.12 -0.35 0.40 0.04
Measles- YoV -8.90 -0.76 -0.02 -0.81
Measles- YoB -0.51 -4.04 -4.34 -4.10
YF- YoV -12.16 -0.84 -8.80 -0.67
YF- YoB -10.37 -7.41 -8.62 -4.66
Impact estimated by the year of vaccination stratification methods as shown in Figs. 2-3. Negative numbers correspond to the IE underestimating and positive numbers
correspond to the IE overestimating the number of deaths averted over 2000–2017
underlying model dynamics and yearly coverage changes.
For measles and YF, this stratification captures a decline
in coverage prior to 2020 which does not occur for
HepB. Additionally it captures any herd protection arising
from post-2020 coverage improvements to varying extents
(seenmore for HepB thanmeasles because of differing age
dynamics; Table 4; Figs. 2E and 3E).
When determining the accuracy of the IE, it is useful to
look at both the relative total difference in deaths averted
over 2000–2017 between the IE and model estimates
(Table 4), and the difference across each year (Figs. 2 and
3). Some of the under- and over-estimation of the IE that
is seen across the years can cancel out when looking at the
aggregated difference over the whole time period. As such,
the IE performs well when looking at the total difference
for no stratification viewed by year of birth for measles,
the activity stratification viewed by year of birth for HepB
and the birth cohort stratification viewed by year of vacci-
nation for measles (Table 4). However, when focusing on
the difference in a specific year, the IE is seen to under-
and over-estimate in certain years (Figs. 2D, 3B and C).
Discussion
We have presented the main methods used by VIMC to
estimate vaccine impact (summarised in Table 3). We also
have shown how these methods perform when provid-
ing an IE. Each of the methods differ and the appropriate
method will depend on the perspective of interest.
The vaccine impact methods primarily differ by
how they attribute impact. The calendar year method
attributes impact to the year examined irrespective of
which age groups are targeted and when the vaccina-
tion occurred. In contrast, impact by birth year attributes
impact to the birth cohorts of interest, irrespective of
when the vaccination occurred over their lifespan. When
only RV occurs in the first year of life, the impact by YoV
and impact by birth year will be similar. However, when
vaccination activities vary in who is targeted and when,
the estimation of impact becomes complex.
The two impact by YoV methods differ not in when
they attribute impact but in the assumptions around how
the effect of vaccination may change over time or by
delivery method. The birth cohort stratification accounts
for changes in transmission and healthcare over time,
allowing the impact of vaccination to be adjusted given
improvements in other interventions such as treatment or
the effects of climate change on vector-borne diseases as
seen for YF [21, 22]. The issue with this method is that it
may be sensitive to the introduction of RV or CV as these
dictate the vaccination experience of cohorts to come, for
example, a birth cohort born the year after a mass vacci-
nation campaign should be well protected by the popu-
lation vaccinated in that campaign. This characteristic is
a strength in that it accounts for herd effects. However,
the denominator for this method does not include vacci-
nations given to birth cohorts vaccinated outside the year
of interest that might have an indirect (herd) effect on the
birth cohort of interest. Furthermore, as the vaccination
coverage, implementation and, arguably, demography are
all subject to high degrees of uncertainty, this characteris-
tic will also exacerbate any inaccuracies.
The most accurate way to capture herd effects would
be to repeatedly run the underlying mathematical mod-
els incrementally, i.e. starting with the baseline and adding
vaccination of a single birth cohort, year and activity type
with each iteration. This has the advantage of correctly
attributing the full indirect impact of each additional set
of vaccinations to the whole population. The disadvantage
of this method is that it is computationally expensive.
Overall, in our examples, we have shown that the IE
works well and is an effective tool to update vaccine
impact. Notably, the activity stratification is accurate for
static models with dose dependency but may overesti-
mate the impact of coverage improvements when dynamic
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herd protection is included. The birth cohort stratifica-
tionmay underestimate impact if coverage declines before
improving in later years.
Caution needs to be taken when deciding the appro-
priateness of implementing an IE. In cases where cov-
erage is reduced drastically or an activity is delayed, if
the pathogen poses a risk of outbreaks and the model is
dynamic, the IE may not be accurate as it may miss cap-
turing the impact of any outbreaks that may occur during
this period. With larger delays to activities, the risks of the
IE not capturing such outbreaks would rise. Additionally,
if a follow-up activity cannot reach the individuals missed,
using the IEmay not be accurate. In such cases, newmodel
runs would be required to provide updated estimates of
vaccine impact.
For computational and time efficiency, the IE is used by
the VIMC to approximate the impact of vaccination given
a new scenario around FVPs relative to the one modelled.
This means that uncertainties in themodelling process are
propagated into the IE. The update was developed in order
to provide estimates on a short timescale given the latest
available demographic and vaccination data.We show that
impact by YoV methods perform well in many situations
and given updates in coverage, each stratification would
be appropriate for their related insights. However, there
are limitations to the IE, particularly for diseases that pose
a risk of outbreaks and that are modelled dynamically, if
there are drastic changes to activities (e.g. coverage drops
or delays to activities) as the IE may not account for rises
in case numbers during such periods. A careful choice
of the impact ratio informed by the natural history of
the disease, individual vaccination strategy and modelling
approach is needed to provide an effective extrapolation.
The impact we show is measured primarily through
mortality; however, there are far reaching benefits of vac-
cination including reduction in morbidity as well is reduc-
ing pressure on health care services shown. The VIMC
uses themethods shown here in a similarmanner for cases
and DALYs (disability adjust life-years); deaths are pre-
sented as there is amore widely accepted, and comparable,
definition of this outcome. Whilst the methods of mod-
elling and impact calculation provide an indication of the
benefits of vaccination, they are limited to very specific
research questions and outcomes. As such, they cannot
replace wider surveys and alternative modelling efforts
to examine the broader benefits of vaccination such as
economic, equity and healthcare improvements.
The methods shown have their strengths but are also
limited in certain ways, and as further research ques-
tions develop, newmethods for calculating vaccine impact
will need to be created. Though the YoV methods cap-
ture changes over time due to healthcare or transmission
variation and the different effects of vaccination activ-
ity, they do not capture issues around vaccination and
healthcare clustering which has been shown to be influ-
ential [3, 23]. An extension would be to account for the
potential of re-vaccinating the same individuals each time,
a method that could highlight and identify groups of zero-
dose children and health equity [24]. Similarly, the current
activity stratification allows us to further explore ques-
tions around vaccine delivery and health access. Finally,
the results shown are presented nationally, whereas RV
and CV may be delivered sub-nationally and the disease
transmission and health access may be spatially hetero-
geneous especially for large countries. As such, the next
steps will be to examine the sensitivity to these national
assumptions and account for the spatial heterogeneity in
vaccine impact.
Whilst vaccination is one of the most effective interven-
tions against infectious diseases, the specific implementa-
tion of vaccination requires substantial planning, support
and financing. Calculating the public health impact of
vaccination and understanding the different methods for
doing so is vital. We have presented multiple methods to
express the complex effects of vaccination which will con-
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